420/250 kDa calculated

TRA-1-81 is expressed upon the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG) and human embryonic stem cells (ES). Both TRA-1-81 and TRA-1-60 recognize antigens that are associated with a pericellular matrix proteoglycan. TRA-1-60 reacts with a sialidase-sensitive epitope while TRA-1-81 reacts with an unknown epitope of the same molecule. TRA-1-81 is commonly used as marker of undifferentiated pluripotent human stem cells and is downregulated upon differentiation. TRA-1-81 has recently been identified as podocalyxin.

This antibody recognizes human TRA-1-81.

Human embryonal carcinoma cell line 2102Ep

Evaluated by Immunocytochemistry in mouse embryonic stem cells (SCR012). Immunocytochemsitry Analysis: A 1:100 dilution of this antibody did not detect TRA-1-81 in mouse embryonic stem cells (SCR012).

Research Category
Stem Cell Research

Research Sub Category
Pluripotent & Early Differentiation

This Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate is validated for use in ICC for the detection of TRA-1-81.

Purified mouse monoclonal IgM conjugated to Cy3 in PBS with 0.1% sodium azide and 15mg/ml BSA.

Maintain refrigerated at 2-8ºC protected from light in undiluted aliquots for up to 6 months from date of receipt.

Control
H9 human embryonic stem cells

Evaluated by Immunocytochemistry in H9 human embryonic stem cells.
Immunocytochemsitry Analysis: A 1:100 dilution of this antibody detected TRA-1-81 in H9 human embryonic stem cells.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.